A non-conserved histidine residue on KRAS drives paralog selectivity of the KRAS G12D inhibitor MRTX1133

Miles A. Keats(National Institutes of Health), Ji Luo(Center for Cancer Research)
bioRxiv (Cold Spring Harbor Laboratory)
December 19, 2022
10.1101/2022.12.16.520846
Cited by 1

Related Papers

Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9
|Proceedings of the National Academy of Sciences|2015|75
A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein
|PLoS ONE|2014|20
A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133
|Cancer Research|2023|19
One-step immortalization of primary human airway epithelial cells capable of oncogenic transformation
|Cell & Bioscience|2016|13